

CIPROVET®
Eye drops

PACKAGE LEAFLET

for veterinary use of the drug product Eye drops Ciprovet®

Approved by: K.A. Savenkov, the Deputy Head of the Federal Service for Veterinary and Phytosanitary Surveillance

(Development organization: NVTs Agrovetzashchita Ltd., bld. 2, 4, Igarskii passage, Moscow, 129329 Russia)

Marketing Authorisation No.: 77-3-4.17-3683 No. IIBP-3-3.6/01655

I. General

The name of the drug product for veterinary use:

Trade name: Eye drops Ciprovet®.

International nonproprietary name: ciprofloxacin.

Dosage form: eye drops.

1 ml of Eye drops Ciprovet® contains 4.5 mg of ciprofloxacin hydrochloride as an active ingredient and benzalkonium chloride, Trilon B, water for injection as excipients.

Appearance: a clear, colorless or light-yellow liquid.

The shelf life of the drug product is 3 years from the date of manufacture and 30 days after the first opening of the vial provided the storage conditions in a closed vial are observed

The drug product is produced in 10 ml polymer dropper bottles sealed with screw-on polymer tamper-evident caps and individually packed in cardboard boxes along with a package leaflet.

Store the drug product in a sealed manufacturer's package protected from direct sunlight, separate from food and feed, at a temperature from 5°C to 25°C.

Keep out of reach of children.

Unused drug product should be disposed in accordance with legal requirements.

Available without a veterinarian's prescription.

II. Pharmacological properties

Eye drops Ciprovet® is an antibacterial anti-inflammatory drug product for topical use in ophthalmology.

Ciprofloxacin hydrochloride, which is part of the drug product, has a bactericidal effect on most gram-positive and gram-negative microorganisms including chlamydia, mycoplasma, Staphylococcus aureus and Pseudomonas aeruginosa including strains of microorganisms resistant to gentamicin.

The mechanism of action of ciprofloxacin hydrochloride consists in inhibition of bacterial DNA gyrase (topoisomerase) - X enzyme, destruction of the DNA structure and disruption of the bacterial cell membrane, which leads to the death of bacteria.

When applied topically, ciprofloxacin penetrates well into the cornea and the anterior chamber of the eye especially when the epithelial layer of the cornea is disturbed.

In terms of the effect upon the animal body Eye drops Ciprovet® can be referred to low hazardous substances (hazard class 4 according to GOST 12.1.007-76), and do not have local irritating and resorptive-toxic effects in recommended doses.

III. Indications:

Eye drops Ciprovet® are prescribed for dogs and cats with the following ophthalmic indications:

- for the treatment of severe and chronic eye diseases: acute and chronic conjunctivitis, keratoconjunctivitis, keratitis, corneal ulcers, septic iridocyclitis, blepharitis;

- in order to reduce the risk of ocular infections after trauma and foreign bodies, as well as for ocular surgery during the preoperative and postoperative periods.

A contraindication to the use of Eye drops Ciprovet® is the increased individual sensitivity of the animal to fluoroquinolones.

Observe the general rules of personal hygiene and safety measures working with Eye drops Ciprovet®. In case of skin or eye contact immediately rinse with plenty of water. People with hypersensitivity to the drug product ingredients should avoid direct contact with Eye drops Ciprovet®. In case of allergic reactions or accidental ingestion of the drug product immediately see a doctor (show a drug package leaflet or a label).

It is prohibited to use drug product empty containers for household purposes they must be disposed with household waste.

Usage of the drug product for animals during pregnancy and lactation, as well as in offspring is determined by a veterinarian based on an assessment of the correspondence of the benefits to the possible risk of its use.

The drug product should not be used in kittens and puppies younger than 7 days of age. Eye drops Ciprovet® should be used with caution in animals with cerebral atherosclerosis and cerebrovascular disease.

Eye drops Ciprovet® are instilled into the conjunctival cavity of the affected eye four times a day at a rate of 1 drop for cats, 1-2 drops for dogs for 7-14 days until the animal's clinical recovery.

Hygienic treatment of the eye is preliminarily carried out in case of abundant purulent or mucopurulent discharge. 3-4 drops are instilled and the exudate is removed with a sterile gauze swab. After that, 1-2 drops of the drug are instilled and treatment is carried out.

As a rule side effects and complications are not observed if the Eye drops Ciprovet® are used in accordance with this package leaflet. In rare cases, the drug can cause mild soreness and conjunctival hyperemia, itching, lacrimation, which disappear within 5 minutes.

If animals develop allergic reactions (conjunctival hyperemia continues or increases), use of the drug product is discontinued.

Symptoms of drug overdose in animals have not been identified.

Eye drops Ciprovet® are incompatible with drug solutions with pH 3-4, which are physically or chemically unstable. When other ophthalmic drugs are used together, the interval between their administrations should be at least 5 minutes.

The side effects of the drug product action during its first use and withdrawal were not observed.

Violations of the dosage schedule should be avoided, as it can lead to decrease in effectiveness. If one dose is missed, the use of the drug should be resumed in the same dose and according to the same dosage schedule.

/AVZ

animal health/

Name and address of the production site of the manufacturer of the drug product for veterinary use:

AVZ S-P LTD., 1, Tsentralnaia str., Sergiyev Posad, Moscow region, 141305 Russia.

Name and address of the organization authorized by the marketing authorization holder or owner of the drug product to accept claims from the consumers: AVZ S-P LTD., 1, Tsentralnaia str., Sergiyev Posad, Moscow region, 141305 Russia.

24-hour hotline: 8-800-700-19-93 (toll free in Russia).

See information on product conformity assessment at: www.vetmag.ru.